Refine by
Solid Tumor Suppliers & Manufacturers
106 companies found
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...
based inCambridge, MASSACHUSETTS (USA)
Foundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. We’re an essential partner to patients, physicians, researchers, and biopharma ...
Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
Neurotrophic tropomyosin-related kinase (NTRK) is a group of high affinity nerve growth factor (NGF) receptors, including tropomyosin receptor kinases (Trk) A, B, and C which are encoded by NTRK1, NTRK2, and NTRK3 genes, respectively. NTRK proteins, ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
Visualize the Landscape of Tissue-Specific Immunity. Tracking T cells in the tissue where they exert their function can advance our understanding of T-cell immunity. MHC I Dextramer® for in-situ staining reagents can detect spatial distribution, ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Trublood is an advanced non-invasive blood test (which provides diagnostically relevant information about cancers via a safe, simple and quick blood draw). Trublood® evaluates blood sample to detect ‘Circulating Tumor Cells’ (CTCs), ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has ...
based inBasel, SWITZERLAND
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of ...
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within tumor tissue. CYAD-203 is currently being evaluated in ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
based inNew Haven, CONNECTICUT (USA)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC ...
based inPalo Alto, CALIFORNIA (USA)
BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity. To ...
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
It is a human monoclonal antibody that can be potentially used in the treatment of Hepatocellular Carcinoma, Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic ...
based inWaltham, MASSACHUSETTS (USA)
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are ...
Natural killer (NK) cells are innate lymphocytes that kill virally infected or malignant cells. Unlike T cells, NK cells function in an antigen independent manner, responding to anything they perceive as "non-self", including malignant cells. NK ...
based inOrlando, FLORIDA (USA)
Asbestos.com is a website and advocacy group that helps the victims of asbestos exposure and their loved ones. We connect our visitors with the resources they need to understand and fight asbestos-related disease, all at no cost. We research the ...
Because living tissues cannot survive in drastically cold conditions, radiologists can use this therapy to induce hypothermia and kill solid tumors such as mesothelioma. This treatment, also known as cryoablation, ...
